Edition:
United Kingdom

Anthera Pharmaceuticals Inc (ANTH.OQ)

ANTH.OQ on NASDAQ Stock Exchange Global Market

1.50USD
8:25pm GMT
Change (% chg)

$0.08 (+5.28%)
Prev Close
$1.42
Open
$1.45
Day's High
$1.50
Day's Low
$1.35
Volume
109,682
Avg. Vol
69,563
52-wk High
$6.23
52-wk Low
$1.21

Latest Key Developments (Source: Significant Developments)

683 Capital Management Reports 6.1 Pct Passive Stake In Anthera Pharma
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - 683 Capital Management Llc :683 CAPITAL MANAGEMENT, LLC REPORTS A 6.1 PERCENT PASSIVE STAKE IN ANTHERA PHARMACEUTICALS INC AS OF JAN 8 - SEC FILING.  Full Article

Anthera Pharmaceuticals files for resale of up to 28.6 million shares of co's common stock
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Anthera Pharmaceuticals Inc ::Anthera Pharmaceuticals Inc files for resale of up to 28.6 million shares of co's common stock by the selling stockholders‍​ .  Full Article

ANTHERA PHARMA REPORTS Q3 LOSS PER SHARE $0.58
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Anthera Pharmaceuticals Inc ::ANTHERA PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS 2017 THIRD QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.58.‍ENDED Q3 OF 2017 WITH CASH AND CASH EQUIVALENTS TOTALING $6.1 MILLION, COMPARED TO $20.8 MILLION AS OF DECEMBER 31, 2016​.  Full Article

Anthera Pharmaceuticals announces pricing of $15 mln private placement offering
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Anthera Pharmaceuticals Inc :Anthera Pharmaceuticals announces pricing of $15 million private placement offering.Anthera Pharma - ‍To use net proceeds from offering for clinical research, development purposes for Sollpura, including result, simplicity, easy trials​.Anthera Pharmaceuticals Inc - ‍Investors have agreed to purchase 2.31 million shares of common stock at $1.25 per share​.  Full Article

Anthera announces positive DSMB review in phase 3 solution study of Sollpura
Tuesday, 16 Aug 2016 

Anthera Pharmaceuticals Inc : Announces positive DSMB review in phase 3 solution study of Sollpura .DSMB had "no concerns regarding safety of data to date, and voted that study continue without modification to protocol or charter.".  Full Article

Anthera Pharmaceuticals Q2 loss per share $0.35
Tuesday, 9 Aug 2016 

Anthera Pharmaceuticals Inc : Q2 loss per share $0.35 .Anthera Pharmaceuticals provides business update and reports 2016 second quarter financial results.  Full Article

Anthera Pharmaceuticals posts Q1 loss of $0.29/share
Monday, 9 May 2016 

Anthera Pharmaceuticals Inc : Anthera Pharmaceuticals provides business update and reports 2016 first quarter financial results . Q1 loss per share $0.29 .Says license and collaborative revenues for quarter ended March 31, 2016 totaled $145,000.  Full Article

BRIEF-Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 Sollpura Study

* ANTHERA ANNOUNCES POSITIVE OUTCOME OF SECOND INTERIM FUTILITY ANALYSIS IN THE PHASE 3 RESULT CLINICAL STUDY OF SOLLPURA: STUDY ON SCHEDULE FOR TOPLINE DATA THIS QUARTER